{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-080039","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.197380+00:00","generated_at":"2026-05-31T20:29:08.168169+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA approves Annovis Bio's transition to new crystal form of Buntanetap for trials","bullets":["FDA approved transition to new crystalline form of Buntanetap for future clinical trials.","Company filed composition of matter patent for new form and provisional patent for manufacturing process in June 2024.","Comprehensive bridge studies in solvents and animals submitted to FDA.","FDA clearance allows a small single-dose bioavailability study in humans as part of transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-080039","json":"https://secwatch.observer/filing/0001104659-24-080039.json","markdown":"https://secwatch.observer/filing/0001104659-24-080039.md","text":"https://secwatch.observer/filing/0001104659-24-080039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924080039/0001104659-24-080039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924080039/tm2419484d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:29:08.168169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}